These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 10674099)
1. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Legros D; Evans S; Maiso F; Enyaru JC; Mbulamberi D Trans R Soc Trop Med Hyg; 1999; 93(4):439-42. PubMed ID: 10674099 [TBL] [Abstract][Full Text] [Related]
2. [Therapeutic failure of melarsoprol among patients treated for late stage T.b. gambiense human African trypanosomiasis in Uganda]. Legros D; Fournier C; Gastellu Etchegorry M; Maiso F; Szumilin E Bull Soc Pathol Exot; 1999 Jul; 92(3):171-2. PubMed ID: 10472443 [TBL] [Abstract][Full Text] [Related]
3. Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo. Balasegaram M; Harris S; Checchi F; Ghorashian S; Hamel C; Karunakara U Bull World Health Organ; 2006 Oct; 84(10):783-91. PubMed ID: 17128358 [TBL] [Abstract][Full Text] [Related]
4. The phenomenon of treatment failures in Human African Trypanosomiasis. Brun R; Schumacher R; Schmid C; Kunz C; Burri C Trop Med Int Health; 2001 Nov; 6(11):906-14. PubMed ID: 11703845 [TBL] [Abstract][Full Text] [Related]
5. Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy. Pépin J; Milord F; Khonde A; Niyonsenga T; Loko L; Mpia B Trans R Soc Trop Med Hyg; 1994; 88(4):447-52. PubMed ID: 7570842 [TBL] [Abstract][Full Text] [Related]
6. Trypanosomiasis relapse after melarsoprol therapy, Democratic Republic of Congo, 1982-2001. Pépin J; Mpia B Emerg Infect Dis; 2005 Jun; 11(6):921-7. PubMed ID: 15963288 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). Schmid C; Richer M; Bilenge CM; Josenando T; Chappuis F; Manthelot CR; Nangouma A; Doua F; Asumu PN; Simarro PP; Burri C J Infect Dis; 2005 Jun; 191(11):1922-31. PubMed ID: 15871127 [TBL] [Abstract][Full Text] [Related]
8. Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis. Nok AJ Parasitol Res; 2003 May; 90(1):71-9. PubMed ID: 12743807 [TBL] [Abstract][Full Text] [Related]
9. Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. Chappuis F; Udayraj N; Stietenroth K; Meussen A; Bovier PA Clin Infect Dis; 2005 Sep; 41(5):748-51. PubMed ID: 16080099 [TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes and risk factors for relapse in patients with early-stage human African trypanosomiasis (HAT) in the Republic of the Congo. Balasegaram M; Harris S; Checchi F; Hamel C; Karunakara U Bull World Health Organ; 2006 Oct; 84(10):777-82. PubMed ID: 17128357 [TBL] [Abstract][Full Text] [Related]
11. Melarsoprol refractory T. b. gambiense from Omugo, north-western Uganda. Matovu E; Enyaru JC; Legros D; Schmid C; Seebeck T; Kaminsky R Trop Med Int Health; 2001 May; 6(5):407-11. PubMed ID: 11348535 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Médecins Sans Frontières programmes. Balasegaram M; Young H; Chappuis F; Priotto G; Raguenaud ME; Checchi F Trans R Soc Trop Med Hyg; 2009 Mar; 103(3):280-90. PubMed ID: 18947846 [TBL] [Abstract][Full Text] [Related]
13. Genetic variants of the TbAT1 adenosine transporter from African trypanosomes in relapse infections following melarsoprol therapy. Matovu E; Geiser F; Schneider V; Mäser P; Enyaru JC; Kaminsky R; Gallati S; Seebeck T Mol Biochem Parasitol; 2001 Sep; 117(1):73-81. PubMed ID: 11551633 [TBL] [Abstract][Full Text] [Related]
14. The efficacy of pentamidine in the treatment of early-late stage Trypanosoma brucei gambiense trypanosomiasis. Doua F; Miezan TW; Sanon Singaro JR; Boa Yapo F; Baltz T Am J Trop Med Hyg; 1996 Dec; 55(6):586-8. PubMed ID: 9025682 [TBL] [Abstract][Full Text] [Related]
15. Genotypic and phenotypic characterization of Trypanosoma brucei gambiense isolates from Ibba, South Sudan, an area of high melarsoprol treatment failure rate. Maina N; Maina KJ; Mäser P; Brun R Acta Trop; 2007; 104(2-3):84-90. PubMed ID: 17765860 [TBL] [Abstract][Full Text] [Related]
16. Novel markers for treatment outcome in late-stage Trypanosoma brucei gambiense trypanosomiasis. Lejon V; Roger I; Mumba Ngoyi D; Menten J; Robays J; N'siesi FX; Bisser S; Boelaert M; Büscher P Clin Infect Dis; 2008 Jul; 47(1):15-22. PubMed ID: 18494605 [TBL] [Abstract][Full Text] [Related]
17. High failure rates of melarsoprol for sleeping sickness, Democratic Republic of Congo. Robays J; Nyamowala G; Sese C; Betu Ku Mesu Kande V; Lutumba P; Van der Veken W; Boelaert M Emerg Infect Dis; 2008 Jun; 14(6):966-7. PubMed ID: 18507916 [TBL] [Abstract][Full Text] [Related]
18. Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Pépin J; Milord F; Khonde AN; Niyonsenga T; Loko L; Mpia B; De Wals P Trans R Soc Trop Med Hyg; 1995; 89(1):92-7. PubMed ID: 7747321 [TBL] [Abstract][Full Text] [Related]
19. Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo. Kazumba LM; Kaka JT; Ngoyi DM; Tshala-Katumbay D PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006504. PubMed ID: 29897919 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of alternative treatments of African gambiense trypanosomiasis in Uganda. Politi C; Carrín G; Evans D; Kuzoe FA; Cattand PD Health Econ; 1995; 4(4):273-87. PubMed ID: 8528430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]